Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 1999

View Archived Issues

U.S. DOD funds study of HupA as neuroprotective agent

High-dose tirilazad mesilate assessed in women with aneurysmal subarachnoid hemorrhage

Celgene reports potent, specific immune responses for thalidomide analogues

Cortecs provides research and development update

Oxford BioMedica and Modex Therapeutiques to develop diabetes therapy

Columbia Laboratories finalizes Crinone license transfer

Phase I trials evaluating J695 now under way

Nastech completes phase III testing of intranasal scopolamine

Perstorp subsidiary merges with Endogen

Bristol-Myers Squibb extends antiinfective collaboration with Cubist Pharmaceuticals

Solvay completes financing for Unimed tender offer, extends tender offer

Disappointing phase II trial results for Ergoset in the treatment of obesity

Structurally novel antitumor and immunosuppressive compounds from Klinge

U.S. patent covers Immucon's novel male contraceptive vaccine technology

Novel gabapentin analogues with anticonvulsant and/or analgesic effects

Neurocrine Biosciences reacquires rights to novel MS treatment

Cytokine suppressors for immune disorders developed at SS Pharm.

Indena presents novel paclitaxel derivatives with excellent antitumor activity

New MMP inhibitors, their preparation and use described by Pfizer scientists

Yoshitomi describes potent, selective tryptase inhibitors

Promising new atypical antipsychotic agent with positive effects on cognition: RGH-1756

WHO develops pyronaridine, an orally active agent for treating chloroquine-resistant malaria

Collaborative antipsychotic R&D yields interesting candidates for development

Inhibitors of protein geranylgeranylation developed at Baldacci as antitumor agents

Roche to develop and market Trimeris's HIV fusion inhibitors

More on PEDF: protein also has ophthalmic indications

Nonsteroidal Rx for atopic dermatitis enters late-stage clinical trials in U.S.

SomatoKine given orphan drug status as treatment of severe burns

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...